{"brief_title": "A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.", "brief_summary": "To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma", "condition": "Carcinoma, Renal Cell", "intervention_type": "Drug", "intervention_name": "SU011248", "description": "50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity", "arm_group_label": "1", "other_name": "Sunitinib, SUTENT", "criteria": "Inclusion Criteria: - Cytokine refractory metastatic renal cell carcinoma with clear cell component - Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy - Prior nephrectomy Exclusion Criteria: - Prior treatment with any systemic therapy other than 1 cytokine therapy - History of or known brain metastases - Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00077974.xml"}